Article Information
History
- September 10, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Paul-Michel Mertes1,
- Xavier Delabranche2,
- Pierre Coliat2,
- Anne Roche1,
- Olivier Collange1,
- Manon Voegelin2,
- Alexandre Bernard2,
- Navreet Dhindsa3,
- Zhenghong Hannah Xu3,
- Bolin Geng3,
- Clet Niyikiza3,
- Victor Moyo3,
- Claire Bourban4,
- Pascal Villa4,
- Alexandre Detappe2,* and
- Xavier Pivot2,*
- 1University Hospital of Strasbourg, France
- 2Institut de Cancérologie Strasbourg Europe, Strasbourg, France
- 3LEAF4Life, Inc. Woburn, MA, USA
- 4Plateforme de chimie Biologique integrative de Strasbourg (PCBIS), UAR 3286 CNRS/Université de Strasbourg, Institut du Médicament de Strasbourg (IMS), Bld Sébastien Brant, 67412 Illkirch-Graffenstaden, France
- ↵*Corresponding Authors:
Xavier PIVOT, Email: x.pivot{at}icans.eu, Tel: + 33 3 68 76 72 90, Alexandre DETAPPE, Email: a.detappe{at}icans.eu
Posted September 10, 2022.
LEAF- 4L6715 enhances oxygenation in patients with acute respiratory distress syndrome (ARDS) due to severe COVID-19: Final results of a phase I/II clinical trial
